Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I hope you are correct HarChris, and we have indeed had a good first quarter.
Biosynex have achieved a margin of 50% recently.
We have historically operated on a 60-70% margin.
And whilst yes I'm sure the demand for our products is diminishing it doesn't put pay to the hope that we had a good Q1 from omicron - if you look at biosynex and read across it would suggest the opposite, that January may have been one of the biggest months for novacyt across the entire pandemic.
Well we're soon to find out what difference going from a business with £1.5m cash and £7m debt to a debt free company with an £105m cash pile makes... I may not be Warren Buffett but I am aware that's the sort of balance sheet improvement that can change the fortunes of a struggling company.
EXMEX -
This web page states 2014:
https://www.labmedica.com/?option=asearch&search=primerdesign
What strategy? We’ve just been told that demand for our products is massively diminishing (puts paid to the hope that we had a good Q1 from omicron.) Unless they’ve got some proper aces up their sleeves (LOL) I expect to see the covid revenue drop be revised to north of 50%. I think a couple of weeks could be a bridge too far for most long suffering shareholders.
Tks ak_gabba. I'm hoping he gives us a carrot that will reward the lth's here won't be going anywhere but something that interests the market would be nice.
Since 2020, why?
At least for one or two Years exmex, if not longer.
Try this link
https://www.labmedica.es/expo/search/7/Novacyt%20/1
How long have Novacyt been using this company to promote their products in Spain and South America?
https://www.labmedica.es/about
https://www.labmedica.es/expo/company/22387/novacyt-group/
Maybe there is going to be some tie-up with Biosynex....It seems strange for a competitor to buy 5% of the company and then go silent?
According to DA we are waiting on an update this month regarding the strategy of the company. Will be interesting to see which products we are looking to launch before the end of this year. Hopefully some non covid products aligned with the increased workflows that PROmate provide. I'm also hopeful of understanding what R&D they have been working on.
Wilson,
Honest answer is nobody outside of the process knows. It was however good to see in table format the current status of all tests submitted from Novacyt to CTDA for review.
Exmex,
Very well spotted! I hadn't noticed that and yes that is the big question!
Completely agree PI100. We can’t sit here like Ad4u / Uk2day dreaming about the next variant that will kill off the human race. We need a robust high revenue generating business with non covid products and MA strategy in order to match future revenues like those seen in 2020.
much better put!!!
worth way north of this sp, WAY NORTH imo
Hi Positive Investor 100. Recovering from a SP of £1.30's. Covid will generate us north of £50m revenue this year. Covid is no longer the hot topic but it will still be generating many millions for ncyt for years to come. Yes, non covid products are the way forward but if you feel so negatively about your holding then surely selling and reinvesting into something you believe in would be a much better strategy for yourself. I hold because I believe I see lots of value here.
its very poor imo,
we should be £4 all day long, £3 by now and MUCH higher, once a few of the missing jigsaw pieces drop into place... ie: dhsc resolved, Bio intention, Tata gameplay, ongoing revenues away from Covid, etc...
again imo
Rifleman - not a chance. Why are figures such as £15 still being bandied around?
DRB recovery from what? We bounced back from mid £1’s and sub cash balance but surely this is just par now? Covid is done and all we know is we may have some non covid stuff in q4 (which we won’t as it’ll be delayed).
I don’t understand what we are recovering from any more, £160m marcap for a firm with massively dwindling sales probably isn’t that bad.
Slightly concerning that we’re in Q2 and still RNS’ing about covid tests which no one cares about. It’s all about non covid, that’s the update we need. Covid test rns’ are very 2020.
Management are best keeping quiet until real news is on the table...the BOD of AVCT go a lot of stick for keeping quiet, but now they have real news the SP has jumped by 100% in the past few weeks, albeit from quite a fall...I think DA will keep his powder dry until the very last minute...
More volume in UK then in France. When are the French switching on the robot? I’m going with 11am.
But reading between the lines tells me that demand is sufficient for the other 9 products.
It's been almost 6 months since the first CTDA RNS so an update on the 11 products was well over due. Can't update us on just the good ones. Need to be open and honest and positive where possible.
NCYT and AVCT are totally different propositions right now. What we have on our side is an unrivalled balance sheet for a company of our size making this about as risk-free as it's possible to get on AIM. What we don't have currently is a management team sharing their vision and selling the potential to investors and institutions. It is *Us* that's being viewed as the diagnostics minnow with nothing but a suite of covid tests, out of ideas if covid testing ever falls completely out of favour.
The potential here is a lot bigger than the market is giving us credit for and I'm happy with what's been unearthed recently (such as with TATA) but the low share price is what you get when the BOD are silent for such a long time and fail to inspire any hope or confidence - hopefully this is all about to change and we're about to see a side to David that we haven't seen up until now.
Maybe I'm just being naive but I'm still confident this comes good in the not too distant future.
BYP -
NCYT shareholders are never going to experience true value, unless the company adopts less secretive ways of announcing deals with the likes of TATA MD and any other 'partnerships'.
From 25.01.2022 Strategy and Full Year 2021 Trading Update RNS
"In the interim, Novacyt continues to build a strong pipeline of business development opportunities for partnership, licensing, and M&A to strengthen the business and accelerate growth."
also from same RNS
"The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates."
Also private testing labs.
IMO, officially, shareholders aren't aware of half of what has been going on, and until that knowledge is in the public domain, we will not realise full value.